Orforglipron vs VK2735: Oral GLP-1 vs Oral Dual Agonist for Obesity

Introduction#

Orforglipron and VK2735 are two of the most closely watched oral obesity drug candidates, each representing a different strategy for delivering incretin-based therapy in pill form. Orforglipron, developed by Eli Lilly, is an oral non-peptide small-molecule GLP-1 receptor agonist that has completed phase 3 trials and is closest to potential market entry. VK2735, developed by Viking Therapeutics, is a dual GLP-1/GIP receptor agonist being developed in both oral and injectable formulations, with phase 2 oral data showing rapid weight loss.

This comparison represents the emerging competitive landscape for oral obesity medications -- a market expected to be worth tens of billions of dollars as patients and physicians seek alternatives to injectable therapies. The two drugs differ in molecular class (small molecule vs peptide), receptor targets (GLP-1 only vs dual GLP-1/GIP), and development stage (phase 3 vs phase 2).

Mechanism of Action Comparison#

Orforglipron#

Orforglipron is a once-daily oral non-peptide small-molecule GLP-1 receptor agonist. Unlike oral semaglutide (Rybelsus), which is a peptide requiring the SNAC absorption enhancer and strict fasting conditions, orforglipron is a synthetic small molecule that activates GLP-1R directly without requiring specialized delivery technology.

The small-molecule design offers several advantages: standard oral bioavailability without fasting requirements, simpler manufacturing than peptide synthesis, and potentially lower cost of goods. Orforglipron activates the same GLP-1R-mediated pathways as injectable agonists -- glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, and central appetite reduction.

VK2735#

VK2735 is a dual GLP-1 and GIP receptor agonist with both oral and injectable formulations. The dual mechanism targets both incretin pathways simultaneously, similar to tirzepatide's approach. GIP receptor co-activation is believed to potentiate the metabolic effects of GLP-1R activation, potentially producing greater weight loss and glycemic improvements than single-target GLP-1 agonism.

The oral VK2735 formulation represents the first dual GLP-1/GIP agonist to demonstrate competitive oral weight loss efficacy in clinical trials. The injectable formulation provides an additional option for patients who prefer or require parenteral administration.

Mechanistic Comparison#

Dosing Comparison#

Orforglipron Dosing#

Orforglipron is administered as a once-daily oral tablet:

• ATTAIN-1 doses: 6 mg, 12 mg, and 36 mg daily over 72 weeks
• Escalation: Gradual dose escalation to target dose
• ATTAIN-MAINTAIN: Studied as oral maintenance therapy after switching from injectable incretins

VK2735 Oral Dosing#

VK2735 oral dosing is investigational:

• VENTURE-Oral: Daily dosing up to 90 mg over 13 weeks
• Maintenance strategy: Exploratory down-titration from 90 mg to 30 mg for weight maintenance
• Injectable alternative: Once-weekly subcutaneous injection also available

Side Effects Comparison#

Orforglipron Side Effects#

Orforglipron's safety profile from ATTAIN-1 was consistent with the established GLP-1 receptor agonist class. The most common adverse events were GI-related: nausea, diarrhea, and vomiting, generally mild to moderate in severity. The overall safety profile was described as consistent with injectable GLP-1 medicines, which is noteworthy because oral delivery might be expected to have different GI tolerability than subcutaneous injection.

VK2735 Side Effects#

VK2735 oral safety data comes from the phase 2 VENTURE-Oral trial. Vomiting was reported in 26% of VK2735-treated subjects compared with 10% placebo. However, 99% of GI-specific adverse events were classified as mild or moderate. The higher vomiting rate is notable but must be interpreted cautiously given the small sample size and short duration of the phase 2 trial.

Safety Comparison Table#

Research Evidence Comparison#

Orforglipron Research#

Orforglipron has the most advanced evidence base among oral obesity candidates:

• ATTAIN-1 (obesity): Phase 3, 72 weeks. Mean weight loss of -7.5% (6 mg), -8.4% (12 mg), -11.2% (36 mg) vs -2.1% placebo. Published in NEJM (2025). 54.6% of 36 mg patients achieved 10% or more loss, 36.0% achieved 15% or more, 18.4% achieved 20% or more
• ATTAIN-2 (obesity + T2D): Phase 3, weight loss up to 9.6% with highest dose. Significant HbA1c reductions
• ATTAIN-MAINTAIN: Phase 3, demonstrated weight maintenance after switching from injectable incretins (Wegovy or Zepbound) to oral orforglipron

Evidence level: High -- completed phase 3 program with NEJM publication.

VK2735 Oral Research#

• VENTURE-Oral: Phase 2, 13 weeks. Up to 12.2% weight loss vs 1.3% placebo. Down-titration maintenance explored.
• VENTURE (subcutaneous): Phase 2, 13 weeks. Up to 14.7% weight loss from baseline. Supports the dual mechanism.

Evidence level: Low -- phase 2 data only, short duration, small sample size.

Key Differences Summary#

• Molecular class: Orforglipron is a non-peptide small molecule (GLP-1 only). VK2735 is a peptide dual agonist (GLP-1 + GIP). Different manufacturing, delivery, and intellectual property profiles.
• Receptor targets: Orforglipron activates GLP-1R only. VK2735 activates both GLP-1R and GIPR. The dual mechanism has been validated by tirzepatide's clinical superiority over semaglutide.
• Weight loss data: Orforglipron 36 mg achieved 11.2% at 72 weeks (phase 3). VK2735 oral achieved 12.2% at 13 weeks (phase 2). The trajectories suggest VK2735 may achieve greater long-term weight loss, but phase 2 results frequently do not replicate in phase 3.
• Development stage: Orforglipron has completed phase 3 and is closest to approval. VK2735 oral has phase 2 data with phase 3 planned.
• Formulation options: VK2735 offers both oral and injectable formulations. Orforglipron is oral only.
• Diabetes data: Orforglipron has phase 3 T2D data (ATTAIN-2). VK2735 has not been studied in diabetes.
• Transition strategy: Orforglipron's ATTAIN-MAINTAIN uniquely demonstrated successful maintenance after switching from injectable therapies, a critical real-world use case.

Conclusion#

Orforglipron and VK2735 represent the two leading approaches to oral obesity pharmacotherapy beyond oral semaglutide. Orforglipron has the clear advantage in evidence maturity, with a completed phase 3 program and NEJM-published results demonstrating meaningful weight loss of up to 11.2% at 72 weeks. Its small-molecule design simplifies manufacturing and oral delivery compared to peptide-based alternatives.

VK2735 counters with a dual GLP-1/GIP mechanism that produced faster weight loss in short-term phase 2 trials (12.2% at 13 weeks) and the flexibility of both oral and injectable formulations. The dual mechanism has been clinically validated by tirzepatide's superiority over single-target GLP-1 agonism, lending biological plausibility to VK2735's potentially greater efficacy.

The critical unknown is whether VK2735's phase 2 trajectory will translate into greater long-term weight loss than orforglipron in phase 3. The history of metabolic drug development shows that phase 2 promise frequently attenuates in larger, longer trials. However, if VK2735 confirms even a portion of its early trajectory, an oral dual agonist achieving greater weight loss than an oral GLP-1 agonist would represent a significant competitive advantage.

Neither drug is currently approved. Orforglipron is expected to reach market first given its more advanced regulatory timeline. The oral obesity market will ultimately have room for multiple agents serving different patient populations and preferences.

Further Reading#

• Orforglipron Overview and Research Guide
• Orforglipron Side Effects
• Orforglipron Dosing Protocols
• VK2735 Overview and Research Guide
• VK2735 Side Effects
• VK2735 Dosing Protocols